Item 8.01. Other Events.
As reported by Titan Pharmaceuticals, Inc. (the "Company") in its Current Report
on Form 8-K, filed with the Securities and Exchange Commission (the
"Commission") on January 4, 2023, the Company received a notice (the "Notice")
from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market
("Nasdaq") that the Company was not in with Listing Rules 5620(a) and
5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting
within twelve months of the December 31, 2021 fiscal year end.
The Company subsequently requested an extension, through June 29, 2023, to hold
a combined annual meeting of stockholders for 2022 and 2023 (the "Annual
Meeting"). On February 28, 2023, Nasdaq granted the Company's request for an
extension through June 29, 2023 to hold a combined Annual Meeting.
The Company previously reported on its Current Report on Form 8-K, filed with
the Commission on February 9, 2023, that the Company planned to hold the Annual
Meeting on April 14, 2023. As a result of Nasdaq's determination, the Company
intends to reschedule the combined Annual Meeting for a date no later than June
29, 2023.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
104 Cover Page Interactive Data (embedded within the Inline XBRL document).
1
© Edgar Online, source Glimpses